Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form
D-Scholarship @ Pitt Banner and Links to Homepage

Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers

Yue, T and Maupin, KA and Fallon, B and Li, L and Partyka, K and Anderson, MA and Brenner, DE and Kaul, K and Zeh, H and Moser, AJ and Simeone, DM and Feng, Z and Brand, RE and Haab, BB (2011) Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS ONE, 6 (12).

[img]
Preview
 PDF
Published Version
Available under License : See the attached license file.
Download (967kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)

Abstract

The CA 19-9 assay detects a carbohydrate antigen on multiple protein carriers, some of which may be preferential carriers of the antigen in cancer. We tested the hypothesis that the measurement of the CA 19-9 antigen on individual proteins could improve performance over the standard CA 19-9 assay. We used antibody arrays to measure the levels of the CA 19-9 antigen on multiple proteins in serum or plasma samples from patients with pancreatic adenocarcinoma or pancreatitis. Sample sets from three different institutions were examined, comprising 531 individual samples. The measurement of the CA 19-9 antigen on any individual protein did not improve upon the performance of the standard CA 19-9 assay (82% sensitivity at 75% specificity for early-stage cancer), owing to diversity among patients in their CA 19-9 protein carriers. However, a subset of cancer patients with no elevation in the standard CA 19-9 assay showed elevations of the CA 19-9 antigen specifically on the proteins MUC5AC or MUC16 in all sample sets. By combining measurements of the standard CA 19-9 assay with detection of CA 19-9 on MUC5AC and MUC16, the sensitivity of cancer detection was improved relative to CA 19-9 alone in each sample set, achieving 67-80% sensitivity at 98% specificity. This finding demonstrates the value of measuring glycans on specific proteins for improving biomarker performance. Diagnostic tests with improved sensitivity for detecting pancreatic cancer could have important applications for improving the treatment and management of patients suffering from this disease. © 2011 Yue et al.

Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Yue, T
Maupin, KA
Fallon, B
Li, L
Partyka, K
Anderson, MA
Brenner, DE
Kaul, K
Zeh, Hhjz1@pitt.eduHJZ1
Moser, AJ
Simeone, DM
Feng, Z
Brand, REreb53@pitt.eduREB53
Haab, BB
Contributors:
ContributionContributors NameEmailPitt UsernameORCID
EditorFraternali, FrancaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Date: 29 December 2011
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 6
Number: 12
DOI or Unique Handle: 10.1371/journal.pone.0029180
Refereed: Yes
MeSH Headings: CA-125 Antigen--blood; CA-19-9 Antigen--blood; Carrier Proteins--blood; Diagnosis, Differential; Humans; Membrane Proteins--blood; Mucin 5AC--blood; Pancreatic Neoplasms--blood; Pancreatic Neoplasms--diagnosis; Protein Array Analysis; Tumor Markers, Biological--blood
Other ID: NLM PMC3248411
PubMed Central ID: PMC3248411
PubMed ID: 22220206
Date Deposited: 13 Sep 2012 15:28
Last Modified: 26 Jan 2019 23:55
URI: http://d-scholarship.pitt.edu/id/eprint/14011

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

Actions (login required)

View Item View Item